Merck KGaA has announced that it has agreed to buy Sigma-Aldrich for $140 per share in cash, or a total of $17 billion.
Merck KGaA has announced that it has agreed to buy Sigma-Aldrich for $140 per share in cash, or a total of $17 billion. The purchase will expand the reach of Merck’s EMD Millipore chemical and equipment division, “increasing the company’s presence in North America and adding exposure to fast-growing Asian markets,” according to a press release from EMD. Sigma-Aldrich is a life-sciences company that specializes in products used in scientific R&D in fields such as biotechnology, genomics, and pharmaceuticals.
Merck said the transaction will be immediately accretive to Merck KGaA, and Sigma-Aldrich will become part of Millipore. The acquisition is touted to be the largest in Merck’s history.
Merck Chairman of the Executive Board Karl-Ludwig Kley said in an interview that with this acquisition, Merck is doubling its business earnings for the academia and lab markets. “Currently we are under-represented in the US and with the strong presence of Sigma-Aldrich in the US market, we’ll have a size which really allows us to take products and service to the customer throughout this great country.”
The transaction is expected to close by mid-2015. Merck expects annual synergies of about €260 million (approximately $333 million), which should be fully achieved within three years after closing, pending regulatory approval.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.